Patents Assigned to Boehringer Ingelheim
-
Patent number: 11999766Abstract: The present invention relates i.a. to a recombinant avian coronavirus spike protein or fragment thereof comprising a mutation at amino acid position 267 to Cysteine. Further, the present invention relates to an immunogenic composition comprising an avian coronavirus with such spike protein.Type: GrantFiled: November 28, 2022Date of Patent: June 4, 2024Assignee: Boehringer Ingelheim Vetmedia GmbHInventors: Annika Kraemer-Kuehl, Thomas Min Stephan, Hans-Christian Philipp
-
Patent number: 11999800Abstract: This invention relates to binding molecules that bind specifically to CD137 and FAP and their use in medicine, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of cancer.Type: GrantFiled: May 18, 2021Date of Patent: June 4, 2024Assignee: Boehringer Ingelheim International GmbHInventors: Eric Borges, Pankaj Gupta, Daniel Christopher Rowe, Justin M. Scheer, Abdallah Souabni, Inigo Tirapu, Joseph Ronald Tumang
-
Patent number: 11992461Abstract: A connecting system for providing a fluidic connection between containers, the connecting system having at least two connecting arrangements configured to produce the fluidic connection. Each container has an initial state in which the two containers are fluidically separated from one another and a connected state in which the two containers have been fluidically connected together by a relative movement of the containers. A securing device prevents relative movement of the containers in the initial state, and a receptacle is provided in which the securing device can be accommodated for enabling said relative movement. The system is usable in a method for preparing a mixture of substances in which the containers are placed in a connecting orientation with the securing device arranged between the containers in a manner preventing fluidic connection of the containers, and releasing the securing device for enabling fluidic connection the containers by a relative connecting movement.Type: GrantFiled: May 28, 2021Date of Patent: May 28, 2024Assignee: Boehringer Ingelheim Vetmedica GmbHInventors: Marcus Rainer Rahmel, Guido Endert, Jonas Ruf, Horst Wergen
-
Patent number: 11992494Abstract: Cyclopentathiophene carboxamides of formula (I), wherein R1, R2, R3, R4, and n are as defined herein, and pharmaceutically acceptable salts thereof. The compounds of formula (I) can be used in methods for the treatment of diseases which can be influenced by antagonizing the activity mediated by the platelet activating factor receptor.Type: GrantFiled: December 19, 2022Date of Patent: May 28, 2024Assignee: Boehringer Ingelheim International GmbHInventors: Matthias Eckhardt, Ferenc Kontes, Christofer Siegfried Tautermann, Dieter Wiedenmayer, Marina Kristina Willwacher
-
Patent number: 11987584Abstract: The present invention relates to heterobicyclic amides and related compounds which are inhibitors of CD38 and are useful in the treatment of cancer.Type: GrantFiled: December 5, 2022Date of Patent: May 21, 2024Assignee: Boehringer Ingelheim International GmbHInventors: Laurie B. Schenkel, Melissa Marie Vasbinder, Kevin Wayne Kuntz, Nicholas Robert Perl, Jennifer Downing
-
Patent number: 11976082Abstract: This invention relates to a novel continuous process for making alkyl 7-amino-5-methyl-[1,2,5]-oxadiazolo¬[3,4-b]pyridine-carboxylate, wherein R is C1-3-alkyl. The process of the invention present invention overcomes disadvantages of processes of the prior art by avoiding the highly energetic intermediates, using readily available and inexpensive starting materials and reagents, and avoiding the isolation of intermediates. The process according to the invention is suitable for use on industrial scale.Type: GrantFiled: May 21, 2021Date of Patent: May 7, 2024Assignee: Boehringer Ingelheim International GmbHInventors: Bernd Werner, Tobias Alt, Andrew T. Brusoe, Frederic Gerard Buono, Michael Klumb, Bjoern Stahl, Thomas G. Tampone
-
Patent number: 11976120Abstract: Provided herein are antibodies that selectively bind to complex comprising a non-classical HLA-I (e.g. HLA-E) and a neoantigen having variable heavy chain domains (VH), variable light chain domains (VL), and complementarity determining regions (CDRs) as disclosed herein, as well as methods and uses thereof.Type: GrantFiled: March 11, 2021Date of Patent: May 7, 2024Assignee: Boehringer Ingelheim International GmbHInventors: Jon Weidanz, Katherine Upchurch-Ange
-
Patent number: 11964102Abstract: An inhaler, preferably for insertion into a nostril, in particular a horse's nostril, with an inhalation valve, which has a movable valve element, whereby the valve element is designed in an annular manner and has an outer edge and an inner edge, whereby the valve element is fastened at the outer edge, the inner edge forms the boundary of an indentation of the valve element, and the inhalation valve has a valve body seat that corresponds to the inner edge.Type: GrantFiled: October 29, 2020Date of Patent: April 23, 2024Assignee: Boehringer Ingelheim Vetmedica GmbHInventors: Marcus Knell, Herbert Wachtel, Guido Endert, Alexander Christ, Horst Wergen
-
Patent number: 11964977Abstract: This invention provides for compounds of the formula: wherein the variables are defined herein, or salt thereof, compositions comprising these compounds, and method for the treatment, control or prevention of a parasitic infestation or infection in an animal in need thereof by administering an effective amount of these compounds to said animal.Type: GrantFiled: May 19, 2021Date of Patent: April 23, 2024Assignee: Boehringer Ingelheim Animal Health USA Inc.Inventors: Hannes Fiepko Koolman, Bart Herlé, Alan Long
-
Patent number: 11964999Abstract: The present invention relates i.a. to a recombinant avian coronavirus spike protein or fragment thereof comprising a mutation at amino acid position 267 to Cysteine. Further, the present invention relates to an immunogenic composition comprising an avian coronavirus with such spike protein.Type: GrantFiled: November 28, 2022Date of Patent: April 23, 2024Assignee: Boehringer Ingelheim Vetmedia GmbHInventors: Annika Kraemer-Kuehl, Thomas Min Stephan, Hans-Christian Philipp
-
Patent number: 11958818Abstract: The present invention relates to compound of formula (I), wherein R1 is chloro, bromo iodo or a brosylate group. The present invention also relates to methods of making this compound and its use in carrying out organic transformations.Type: GrantFiled: April 29, 2020Date of Patent: April 16, 2024Assignee: Boehringer Ingelheim International GmbHInventor: Nitinchandra D. Patel
-
Patent number: 11952418Abstract: The invention provides novel biparatopic LRP5/LRP6 cross-reactive binding polypeptides, and more specifically novel biparatopic LRP5/LRP6 cross-reactive immunoglobulin single variable domain constructs which can inhibit Wnt signaling pathways. The invention also relates to specific sequences of such polypeptides, methods of their production, and methods of using them, including methods of treatment of diseases such as cancer.Type: GrantFiled: February 12, 2020Date of Patent: April 9, 2024Assignee: Boehringer Ingelheim International GmbHInventors: Vittoria Zinzalla, Klaus-Peter Kuenkele, Marie-Ange Buyse, Karen Cromie, Stephanie Staelens, Beatrijs Strubbe
-
Patent number: 11952377Abstract: The present invention relates to bicyclic heterocycle compounds of Formula (I): and pharmaceutically acceptable salts thereof, which are inhibitors of CD38 and are useful in the treatment of cancer.Type: GrantFiled: January 28, 2022Date of Patent: April 9, 2024Assignee: Boehringer Ingelheim International GmbHInventors: Jennifer Downing, Kevin Wayne Kuntz, Laurie B. Schenkel, Melissa Marie Vasbinder
-
Patent number: 11945812Abstract: The present invention encompasses compounds of formula (I) wherein R1a, R1b, R2a, R2b, Z, R3 to R5, A, p, U, V, W, L and E have the meanings given in the claims and specification, their use as inhibitors of mutant Ras family proteins, pharmaceutical compositions and preparations containing such compounds and their use as medicaments/medical uses, especially as agents for treatment and/or prevention of oncological diseases.Type: GrantFiled: June 1, 2021Date of Patent: April 2, 2024Assignees: Boehringer Ingelheim International GmbH, Vanderbilt UniversityInventors: Jason Abbott, Joachim Broeker, Jianwen Cui, Steve W. Fesik, Andreas Gollner, Tim Hodges, Jale Karolyi-Oezguer, Andrew Little, Andreas Mantoulidis, Jason Phan, Dhruba Sarkar, Christian Alan Paul Smethurst, Qi Sun, Matthias Treu, Alex Waterson
-
Patent number: 11933697Abstract: The invention relates to a method for closed sampling from filling plants comprising the following steps in: filling a sample quantity into a container (1) with a wall (3); applying a reinforcing element (20) to the container (1) with the wall; introducing a fracture point (22) into the wall of the container (1) in the area of the reinforcing element (20); introducing a sampling attachment (30) with hollow tube (40) into the wall of the container (1) in the area of the fracture point (22); filling a sample container (50) connected to the hollow tube (40) once or several times; removing the sample container (50) from the hollow tube (40) and closing the sample container (50); removing the sampling attachment (30) with hollow tube (40) from the container; and sealing the fracture point (22) of the container in the area of the reinforcing element (20). The subject matter of the invention is also a sampling device, in particular for carrying out the method.Type: GrantFiled: April 29, 2019Date of Patent: March 19, 2024Assignee: Boehringer Ingelheim International GmbHInventors: Thomas Wirth, Tim Baatz, Georg Dziewas
-
Patent number: 11925951Abstract: The disclosure relates to an extended-range spray applicator, and methods of making and use thereof, for dosing vaccines and/or probiotics to avian animals at a distance.Type: GrantFiled: February 23, 2021Date of Patent: March 12, 2024Assignee: BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC.Inventors: Christopher Davis Leslie, Ludovic Porcher
-
Patent number: 11918596Abstract: The present invention relates to certain SGLT-2 inhibitors for treating and/or preventing oxidative stress, for example in patients with type 1 or type 2 diabetes, as well as to the use of such SGLT-2 inhibitors in treatment and/or prevention of cardiovascular diseases in patients, for example type 1 or type 2 diabetes patients. The present invention further relates to certain SGLT-2 inhibitors for treating and/or preventing a metabolic disorder and preventing, reducing the risk of or delaying the occurrence of a cardiovascular event in patients, for example patients with type 1 or type 2 diabetes.Type: GrantFiled: July 21, 2021Date of Patent: March 5, 2024Assignee: Boehringer Ingelheim International GmbHInventors: Uli Christian Broedl, Odd-Erik Johansen, Gabriel Woojai Kim, Eric Williams Mayoux, Afshin Salsali, Nima Soleymanlou, Maximilian von Eynatten, Hans-Juergen Woerle, David Z. I. Cherney, Bruce A. Perkins, Andreas Daiber, Thomas Muenzel
-
Patent number: 11919903Abstract: The invention relates to polymorphous crystal modifications of a DPP-IV inhibitor, the preparation thereof and the use thereof for preparing a medicament.Type: GrantFiled: June 30, 2021Date of Patent: March 5, 2024Assignee: Boehringer Ingelheim International GmbHInventors: Peter Sieger, Dirk Kemmer, Peter Kohlbauer, Thomas Nicola, Martin Renz
-
Patent number: 11911388Abstract: The present invention relates to the finding that certain DPP-4 inhibitors are particularly suitable for treating and/or preventing metabolic diseases, particularly diabetes, in patients with insufficient glycemic control despite a therapy with an oral and/or a non-oral antidiabetic drug.Type: GrantFiled: February 11, 2021Date of Patent: February 27, 2024Assignee: Boehringer Ingelheim International GmbHInventors: Eva Ulrike Graefe-Mody, Thomas Klein, Michael Mark, Hans-Juergen Woerle
-
Patent number: 11911387Abstract: The present invention relates to certain DPP-4 inhibitors for treating and/or preventing oxidative stress, vascular stress and/or endothelial dysfunction as well as to the use of such DPP-4 inhibitors in treatment and/or prevention of diabetic or non-diabetic patients, including patient groups at risk of cardiovascular and/or renal disease.Type: GrantFiled: December 15, 2020Date of Patent: February 27, 2024Assignee: Boehringer Ingelheim International GmbHInventors: Thomas Klein, Andreas Daiber, Odd-Erik Johansen, Michael Mark, Sanjaykumar Patel, Hans-Juergen Woerle